Dexcom Reports Q3 2026 Earnings, Raises Guidance, and Authorizes $1.0B Share Buyback

DexCom, Inc. (DXCM) Form 8-K Analysis: Q3 2026 Earnings & Capital Allocation

1. Key Event Summary

On October 29, 2026, DexCom, Inc. filed a Current Report on Form 8-K under Items 2.02 and 8.01 disclosing:

• Q3 2026 Financial Results: Revenue of $1.344 billion, representing 11% year-over-year growth on both a reported and organic basis.
• Guidance Updates: Dexcom raised the midpoint of its full-year 2026 revenue guidance to $5.20–$5.25 billion (~12–13% growth) and increased non-GAAP operating margin guidance to approximately 24%.
• New $1.0 Billion Share Repurchase Program: Dexcom's Board of Directors authorized a share repurchase program of up to $1.0 billion of common stock expiring no later than December 31, 2027.

2. Q3 2026 Financial Highlights

• Revenue: $1.344 billion vs. $1.209 billion in Q3 2025 (+11% YoY).
  • U.S. revenue grew 14% YoY.
  • International revenue grew 5% YoY.
• Gross Margin:
  • GAAP Gross Profit: $864.4 million (64.3% margin) vs. 60.5% in Q3 2025.
  • Non-GAAP Gross Profit: $875.3 million (65.1% margin) vs. 61.3% in Q3 2025.
• Operating Income:
  • GAAP: $327.2 million (24.3% margin, +420 bps YoY).
  • Non-GAAP: $339.5 million (25.3% margin, +270 bps YoY).
• Net Income & EPS:
  • GAAP Net Income: $275.1 million, or $0.72 per diluted share.
  • Non-GAAP Net Income: $275.0 million, or $0.73 per diluted share (up from $0.61 in Q3 2025).
• Balance Sheet & Cash: $1.82 billion in total cash, cash equivalents, and marketable securities as of September 30, 2026; credit facility remains undrawn.

3. Strategic & Capital Allocation Implications

• Share Buyback Authorization: The $1.0 billion repurchase authorization demonstrates capital return confidence given the company's strong cash position ($1.82B) and continuing positive cash flows.
• Clinical and Commercial Momentum: Recent NEJM publication of the CONNECT clinical trial supports broader adoption of Dexcom G7 among Type 2 diabetes patients not on insulin, complemented by the launch of the updated Stelo platform and ongoing international rollout of the G7 15-day sensor platform.